Application of Omics and Systems Medicine in Bladder Cancer

Basit Öğe Kaydı
dc.contributor.authorFrantzi M.
dc.contributor.authorLatosinska A.
dc.contributor.authorAkand M.
dc.contributor.authorMerseburger A.S.
dc.date.accessioned2020-03-26T19:43:42Z
dc.date.available2020-03-26T19:43:42Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBladder cancer (BC) is the ninth most common cancer in the world. Smoking remains the main disease risk factor which is responsible for about half of the diagnosed BC cases. Although the vast majority (~75%) of BC cases are diagnosed at an early stage, the recurrence rate is reaching up to 78%. Thus, frequent monitoring is required. Since cystoscopy, the current diagnostic procedure, is highly invasive, disease monitoring is associated with increased patient incompliance and high disease-related costs. However, the limitations of the alternative diagnostic means (suboptimal accuracy of cytology and/or noninvasive markers) underscore the need for the development of novel diagnostic approaches. Apart from the diagnostic complications, the current therapeutic options for BC are also limited. The high disease heterogeneity at the molecular level presents significant challenges for biomarker translational research, as well as for drug development trials. In order to overcome the difficulties associated with the inter- and intratumor variability, the application of -omics approaches and systems medicine will greatly help to address the disease heterogeneity. The application of high-resolution -omics datasets has recently gained more popularity in several applications, such as: (i) BC disease characterization, (ii) patient stratification for therapy decision-making, and (iii) diagnostic and prognostic biomarker development. The concept of applying systems medicine to answer the above clinical questions paves a new avenue toward precision and personalized medicine. This chapter aims at providing an overview of the BC pathophysiology and main clinical needs that remain to be addressed. Along these lines, research efforts to address these clinical demands will be summarized, mainly focused on the use of state-of-the-art "OMICS" methodologies. © 2018 John Wiley & Sons, Inc.en_US
dc.identifier.doi10.1002/9781119183952.ch21en_US
dc.identifier.endpage360en_US
dc.identifier.isbn9781119183952; 9781119181149
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage347en_US
dc.identifier.urihttps://dx.doi.org/10.1002/9781119183952.ch21
dc.identifier.urihttps://hdl.handle.net/20.500.12395/35737
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherwileyen_US
dc.relation.ispartofIntegration of Omics Approaches and Systems Biology for Clinical Applicationsen_US
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subject-omicsen_US
dc.subjectBiomarkersen_US
dc.subjectBladder canceren_US
dc.subjectDrug targetsen_US
dc.subjectSystems medicineen_US
dc.titleApplication of Omics and Systems Medicine in Bladder Canceren_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu